1. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
- Author
-
Daniela Maria Tanase, Claudia Florida Costea, Mariana Floria, Alina Ecaterina Jucan, Ciprian Rezus, Manuela Ciocoiu, Claudia Cristina Tarniceriu, Cristina Lăcătuşu, Evelina Maria Gosav, and Daniela Petrov
- Subjects
Ceramide ,Medicine (General) ,Clinical Biochemistry ,Disease ,Oxidative phosphorylation ,Review ,Bioinformatics ,therapeutic targets ,chemistry.chemical_compound ,R5-920 ,Diabetes mellitus ,NAFLD ,medicine ,ceramide ,sphingolipids ,business.industry ,Fatty liver ,SL ,non-alcoholic fatty liver disease ,biomarkers ,medicine.disease ,Sphingolipid ,Lipotoxicity ,chemistry ,ATS ,Steatosis ,atherosclerosis ,business - Abstract
Non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (ATS) are worldwide known diseases with increased incidence and prevalence. These two are driven and are interconnected by multiple oxidative and metabolic functions such as lipotoxicity. A gamut of evidence suggests that sphingolipids (SL), such as ceramides, account for much of the tissue damage. Although in humans they are proving to be accurate biomarkers of adverse cardiovascular disease outcomes and NAFLD progression, in rodents, pharmacological inhibition or depletion of enzymes driving de novo ceramide synthesis prevents the development of metabolic driven diseases such as diabetes, ATS, and hepatic steatosis. In this narrative review, we discuss the pathways which generate the ceramide synthesis, the potential use of circulating ceramides as novel biomarkers in the development and progression of ATS and related diseases, and their potential use as therapeutic targets in NAFDL-ATS development which can further provide new clues in this field.
- Published
- 2021